Quantum Hamiltonian Reduction in Superspace Formalism

Recently the quantum hamiltonian reduction was done in the case of general $s\ell(2)$ embeddings into Lie algebras and superalgebras. In this paper we extend the results to the quantum hamiltonian reduction of $N=1$ affine Lie superalgebras in the superspace formalism. We show that if we choose a gauge for the supersymmetry, and consider only certain equivalence classes of fields, then our quantum hamiltonian reduction reduces to quantum hamiltonian reduction of non-supersymmetric Lie superalgebras. We construct explicitly the super energy-momentum tensor, as well as all generators of spin 1 (and \hf); thus we construct explicitly all generators in the superconformal, quasi-superconformal and $\Z_2 \times \Z_2$ superconformal algebras.Comment: 13 pages latex, ENSLAPP-A-45

Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins:The PharmLines initiative

Objective: To investigate whether statin adherence (defined as proportion days covered, PDC) is associated with LDL-c response in statin initiators on standard and low starting doses of statins, and to detect a possible interaction with sex. Methods: An inception cohort study was conducted using the PharmLines Initiative, a linkage between the Lifelines Cohort Study and the University of Groningen's IADB.nl (prescription database). First-time statin users were followed from baseline to follow-up measurement. We matched participants (1:1) between the standard-dose and the low-dose group of statin users on the duration of follow-up. Multiple linear regression analysis was used to model the association. Results: In univariate analysis, PDC was significantly associated with LDL-c response similarly (slope = -0.021), in both the standard-dose group (N = 115, p < .001) and the low-dose group (N = 115, p = .003). In the standard-dose group, the same level of PDC appeared to be significantly associated with a greater LDL-c level reduction in women (slope = -0.027, N = 48, p < .001) than in men (slope = -0.017, N = 67, p < .001). Meanwhile, in the low-dose group, the reduction of LDL-c level from baseline seemed to be greater in men (slope = -0.023, N = 56, p < .001) than in women (slope = -0.020, N = 59, p < .001) for the same level of PDC. In multiple regression analysis, the significant association between PDC and LDL-c with a similar pattern to the univariate result was maintained only in the standard-dose group. Conclusions: Adherence is significantly associated with LDL-c response to statins at follow-up. Sex appears to significantly modify this association. At a similar adherence level, women seem to experience a better LDL-c response to standard-dose statins compared to men in a real-world setting

Sex disparities in the effect of statins on lipid parameters:The PharmLines Initiative

Real-world evidence on a potential statin effect modification by sex is inconclusive, especially for the primary prevention of cardiovascular disease (CVD). We aimed to quantify the differences in the effect of statins on lipid parameters between men and women. The PharmLines Initiative linked the Lifelines Cohort Study and the IADB.nl prescription database. This database covers a representative population from the Netherlands. We selected participants aged ≥40 years at the index date: the date of the first prescription of any statin monotherapy in the study period 2006 to 2017. Multivariate regression modeling was used to compare the difference of the mean percentage change of lipid parameters (% mean difference [MD]) from baseline to follow-up measurement between the sexes. Out of 5366 statin users from approximately 50,000 participants available in the final linked database, 685 were statin initiators. At baseline, women had significantly higher levels of mean total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) than men (all P values <.01). At follow-up, women had a significantly higher mean percentage change of HDL-C compared to men (adjusted % MD 5.59, 95% confidence interval [CI] 2.42-8.75, P < .01). There was no significant sex difference in other parameters, nor in the proportion of men and women who achieved LDL-C ≤2.5 mmol/L. Statins appear to have a greater effect on increasing HDL-C levels in women than men while showing similar effect on other lipid parameters in both sexes. Men should not be treated differently than women

chi^2 Analysis of Supersymmetric Models

We discuss the results of a global fit to precision data in supersymmetric models. We consider both gravity- and gauge-mediated models. As the superpartner spectrum becomes light, the global fit to the data typically results in larger values of chi^2. We indicate the regions of parameter space which are excluded by the data. We discuss the additional effect of the B(B --> X_s\gamma) measurement. Our analysis excludes chargino masses below MZ in the simplest gauge-mediated model with mu>0, with stronger constraints for larger values of tan beta.Comment: 11 pages, 13 figures. Talk given by D.M.P. at the 5th International Conference on Supersymmetries in Physics (SUSY 97), Philadelphia, Pennsylvania, May 27-31, 199

Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative

Real-world evidence on a potential statin effect modification by sex is inconclusive, especially for the primary prevention of cardiovascular disease (CVD). We aimed to quantify the differences in the effect of statins on lipid parameters between men and women. The PharmLines Initiative linked the Lifelines Cohort Study and the IADB.nl prescription database. This database covers a representative population from the Netherlands. We selected participants aged ≥40years at the index date: The date of the first prescription of any statin monotherapy in the study period 2006 to 2017. Multivariate regression modeling was used to compare the difference of the mean percentage change of lipid parameters (% mean difference [MD]) from baseline to follow-up measurement between the sexes. Out of 5366 statin users from approximately 50,000 participants available in the final linked database, 685 were statin initiators. At baseline, women had significantly higher levels of mean total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and highdensity lipoprotein cholesterol (HDL-C) than men (all P values <.01). At follow-up, women had a significantly higher mean percentage change of HDL-C compared to men (adjusted%MD 5.59, 95% confidence interval [CI] 2.42-8.75, P<.01). There was no significant sex difference in other parameters, nor in the proportion of men and women who achieved LDL-C ≤2.5mmol/L. Statins appear to have a greater effect on increasing HDL-C levels in women than men while showing similar effect on other lipid parameters in both sexes. Men should not be treated differently than women

Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort:The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study

BACKGROUND: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation. METHODS: we measured plasma pyridoxal 5'-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease. As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1-57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8-8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred. In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47-0.93). However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51-1.01) and 0.74 (95% confidence interval, 0.53-1.05). The association of plasma PLP with cardiovascular risk was modified by gender (adjusted Pinteraction = 0.04). When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27-0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65-1.51). CONCLUSIONS: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation. Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women

Natriuretic peptides and integrated risk assessment for cardiovascular disease. an individual-participant-data meta-analysis

BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment. METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure. FINDINGS: We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56-1·98) for the combination of coronary heart disease and stroke and 2·00 (1·77-2·26) for the combination of coronary heart disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing conventional risk factors was associated with a C-index increase of 0·012 (0·010-0·014) and a net reclassification improvement of 0·027 (0·019-0·036) for the combination of coronary heart disease and stroke and a C-index increase of 0·019 (0·016-0·022) and a net reclassification improvement of 0·028 (0·019-0·038) for the combination of coronary heart disease, stroke, and heart failure. INTERPRETATION: In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly predicted first-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease primary prevention

Bounds on Supersymmetry from Electroweak Precision Analysis

The Standard Model global fit to precision data is excellent. The Minimal Supersymmetric Standard Model can also fit the data well, though not as well as the Standard Model. At best, supersymmetric contributions either decouple or only slightly decrease the total chi^2, at the expense of decreasing the number of degrees of freedom. In general, regions of parameter space with large supersymmetric corrections from light superpartners are associated with poor fits to the data. We contrast results of a simple (oblique) approximation with full one-loop results, and show that for the most important observables the non-oblique corrections can be larger than the oblique corrections, and must be taken into account. We elucidate the regions of parameter space in both gravity- and gauge-mediated models which are excluded. Significant regions of parameter space are excluded, especially with positive supersymmetric mass parameter mu. We give a complete listing of the bounds on all the superpartner and Higgs boson masses. For either sign of mu, and for all supersymmetric models considered, we set a lower limit on the mass of the lightest CP-even Higgs scalar, mh > 78 GeV. Also, the first and second generation squark masses are constrained to be above 280 (325) GeV in the supergravity (gauge-mediated) model.Comment: 32 pages, 12 figures; SLAC-PUB number change

SN 2021hpr and its two siblings in the Cepheid calibrator galaxy NGC 3147: A hierarchical BayeSN analysis of a Type Ia supernova trio, and a Hubble constant constraint

To improve Type Ia supernova (SN Ia) standardisability, the consistency of distance estimates to siblings -- SNe in the same host galaxy -- should be investigated. We present Young Supernova Experiment Pan-STARRS-1 $grizy$ photometry of SN 2021hpr, the third spectroscopically confirmed SN Ia in the high-stellar-mass Cepheid-calibrator galaxy NGC 3147. We analyse NGC 3147's trio of SN Ia siblings: SNe 1997bq, 2008fv and 2021hpr, using a new version of the BayeSN model of SN Ia spectral-energy distributions, retrained simultaneously using optical-NIR $BgVrizYJH$ (0.35--1.8 $\mu$m) data. The distance estimates to each sibling are consistent, with a sample standard deviation $\lesssim$0.01 mag, much smaller than the total intrinsic scatter in the training sample: $\sigma_0\approx0.09$ mag. Fitting normal SN Ia siblings in three additional galaxies, we estimate a $\approx$90% probability that the siblings' intrinsic scatter is smaller than $\sigma_0$. We build a new hierarchical model that fits light curves of siblings in a single galaxy simultaneously; this yields more precise estimates of the common distance and the dust parameters. Fitting the trio for a common dust law shape yields $R_V=2.69\pm0.52$. Our work motivates future hierarchical modelling of more siblings, to tightly constrain their intrinsic scatter, and better understand SN-host correlations. Finally, we estimate the Hubble constant, using a Cepheid distance to NGC 3147, the siblings trio, and 109 Hubble flow ($0.01 < z_{\rm{CMB}} < 0.08$) SNe Ia; marginalising over the siblings' and population's intrinsic scatters, and the peculiar velocity dispersion, yields $H_0=77.9\pm6.5 \text{ km s}^{-1}\text{Mpc}^{-1}$.Comment: Submitted to MNRAS; 30 pages, 22 figure